Ms. Li continued, "China Pharma is experienced in bringing world leading medicines to the Chinese market. We believe that Rosuvastatin provides us with an exciting opportunity to extend our product portfolio, and expect it to create value for patients and our shareholders over time."
(1) Source: BMJ 2003 June: 326 (7404):1423. Law MR et al. "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis."
(2) Source: AstraZeneca 2007 Annual Report and Form 20-F Information
(3) Source: Am J Cardiol. 2003 July 15;91(5A):20C-23C; Jones PH et al. "Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with
rapidly growing profit that develops, manufactures, and markets treatments for
a wide range of high incidence and high mortality conditions in China,
including cardiovascular, CNS, infectious, and digestive diseases. The
Company's cost-effective, high margin business model is driven by market
demand and supported by eight scalable GMP-certified product lines covering
the major dosage forms. In addition, the Company has a broad and expanding
distribution network across 30 provinces, municipalities and autonomous
regions. The Company is registered in Delaware, USA. Hainan Helpson Medical &
Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province,
China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more
information about China Pharma Holdings, Inc., please visit
|SOURCE China Pharma Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved